Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

Abstract Background Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) in two phase 3 studies (MEASURE 1 and MEASURE 2). Here, we present 52-week results from the MEASURE 3 study assessing the efficacy and safety of secukinumab 30...

Full description

Bibliographic Details
Main Authors: Karel Pavelka, Alan Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Luminita Pricop, Mats Andersson, Aimee Readie, Brian Porter
Format: Article
Language:English
Published: BMC 2017-12-01
Series:Arthritis Research & Therapy
Subjects:
Secukinumab
IL-17
Ankylosing spondylitis
Biologic therapy
Online Access:http://link.springer.com/article/10.1186/s13075-017-1490-y

Internet

http://link.springer.com/article/10.1186/s13075-017-1490-y

Similar Items